Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population
- PMID: 2297455
- PMCID: PMC1380068
- DOI: 10.1111/j.1365-2125.1990.tb03609.x
Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population
Abstract
The study was aimed at defining the relationships among the oxidative capacities for three prototype drugs, metoprolol, debrisoquine and sparteine, used for assessing genetically determined polymorphism of drug oxidation in a Japanese population. Among 292 unrelated healthy Japanese subjects who had been defined as extensive (EMs, n = 291) or poor (PM, n = 1) metabolisers of metoprolol oxidation, 55 subjects (EMs = 54 and PM = 1) were selected. One PM of metoprolol oxidation was also identified as a PM not only of debrisoquine but also of sparteine, and no misclassification by the three phenotypic methods was observed. All three correlations among the metabolic ratios of the three test probes assessed by Spearman's rank test were highly significant (P less than 0.001). These findings indicate that in Japanese subjects the oxidation capacities of metoprolol, debrisoquine, and sparteine are closely related. It appears that in Japanese the polymorphic oxidation of the three drugs is co-regulated, either by the same enzyme or gene-controlling system.
Similar articles
-
Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.Eur J Drug Metab Pharmacokinet. 1996 Oct-Dec;21(4):309-14. doi: 10.1007/BF03189732. Eur J Drug Metab Pharmacokinet. 1996. PMID: 9074895
-
Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.Pharmacogenetics. 1992 Apr;2(2):89-92. doi: 10.1097/00008571-199204000-00006. Pharmacogenetics. 1992. PMID: 1302046
-
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29. Clin Pharmacol Ther. 1982. PMID: 7056024
-
Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.Pharmacol Toxicol. 1990 Oct;67(4):273-83. doi: 10.1111/j.1600-0773.1990.tb00830.x. Pharmacol Toxicol. 1990. PMID: 2077517 Review.
-
Polymorphic oxidation of debrisoquine and sparteine.Prog Clin Biol Res. 1986;214:157-67. Prog Clin Biol Res. 1986. PMID: 3523506 Review. No abstract available.
Cited by
-
Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.Eur J Drug Metab Pharmacokinet. 1996 Oct-Dec;21(4):309-14. doi: 10.1007/BF03189732. Eur J Drug Metab Pharmacokinet. 1996. PMID: 9074895
-
S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.Br J Clin Pharmacol. 1994 Nov;38(5):463-5. doi: 10.1111/j.1365-2125.1994.tb04383.x. Br J Clin Pharmacol. 1994. PMID: 7893589 Free PMC article. Clinical Trial.
-
Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.Clin Pharmacokinet. 1995 Sep;29(3):192-209. doi: 10.2165/00003088-199529030-00005. Clin Pharmacokinet. 1995. PMID: 8521680 Review.
-
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19817501 Review.
-
The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.Br J Clin Pharmacol. 1993 Apr;35(4):426-30. doi: 10.1111/j.1365-2125.1993.tb04161.x. Br J Clin Pharmacol. 1993. PMID: 8485023 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources